Abstract PD10-02: I- SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+ HER2-negative breast cancer (BC)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: J. Chien, R. M. Mukhtar, C. Yau, A. D. Elias, A. M. Wallace, N. Chan, C. Omene, N. Chen, J. Tseng, M. S. Trivedi, E. Stringer-Reasor, D. Yee, A. S. Clark, A. Thomas, H. Han, M. Arora, C. Nangia, K. Albain, C. Falkson, C. Isaacs, A. Zimmer, M. Rozenblit, L. van't Veer, L. Brown Swigart, G. Hirst, W. Symmans, A. D. Borowsky, N. Onishi, N. Hylton, S. Alkhafaji, K. V. Giridhar, C. Vaklavas, M. Wei, M. P. Goetz, O. Olopade, L. Huppert, C. Wu, L. J. Esserman
Institutions: University of California, San Francisco, University of Colorado Anschutz, University of California San Diego, NYU Langone Health, New York University, Rutgers Cancer Institute, University of Chicago, City Of Hope National Medical Center, Columbia University Irving Medical Center, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, University of Minnesota, University of Pennsylvania, Duke Cancer Institute, Moffitt Cancer Center, UC Davis Comprehensive Cancer Center, Loyola University Chicago, University of Rochester Medicine, University of Rochester, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Oregon Health & Science University, Yale Cancer Center, The University of Texas MD Anderson Cancer Center, University of California Davis Medical Center, University of California, Davis, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), University of Utah, Huntsman Cancer Institute
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7129278233